A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

Emmanuel S. Antonarakis,Elisabeth I. Heath,David C. Smith,Dana E. Rathkopf,Amanda Blackford,Daniel C. Danila,Serina King,Anja Frost,M. A. Carducci

A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

2011

Emmanuel S. Antonarakis
Elisabeth I. Heath
David C. Smith
Dana E. Rathkopf
Amanda Blackford
Daniel C. Danila
Serina King
Anja Frost
M. A. Carducci

4532 Background: The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling, and delays tumor growth in murine prostate cancer xenograft models. Unlike ketoconazole, it does not ...

Keywords:

Urology
Itraconazole
Castration
Phases of clinical research
Physical therapy
Prostate cancer
Gynecology
Medicine
Hedgehog signaling pathway
Ketoconazole
Internal medicine
antifungal drug
Pathology
Angiogenesis
Pharmacology
castration resistant
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations